Tmunity Therapeutics

19 articles with Tmunity Therapeutics

• Be The Match BioTherapies® and Tmunity Announce Collaboration to Support Clinical Trials of Next-Generation Immunotherapies

  7/9/2019

  Partnership will accelerate access to novel therapeutics for patients with devastating diseases

• Tmunity Announces June 2019 Investor Conference Schedule

  5/23/2019

  Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at an investor conference in June 2019.

• Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers

  5/1/2019

  Collaboration will broaden Tmunity’s pipeline to include a glioma T cell therapy engineered to express a newly discovered T cell receptor

• 

  First U.S. Patients Are Treated With CRISPR as Echoes of Scandal in China Still Linger

  4/17/2019

  The first clinical trials using CRISPR technology are expected to get underway in the United States, even as echoes of a scandal involving the use of CRISPR on embryos in China are still being felt across the globe.

• Tmunity Announces Participation at Four Upcoming Investor Conferences

  3/1/2019

  Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at four investor conferences in March 2019.

• Tmunity Appoints Patrick Gray and Garry Nicholson to its Board of Directors as Independent Directors

  2/14/2019

  Tmunity Therapeutics is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy

• Tmunity to Present at the 37th Annual J.P. Morgan Healthcare Conference

  12/21/2018

  Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference

• 

  19 (at Least!) of TIME Magazine’s 50 Most Influential Healthcare People Have Biopharma Ties

  10/19/2018

  TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.

• FierceBiotech Names Tmunity as One of Its “Fierce 15” Biotech Companies of 2018

  10/2/2018

  Tmunity Therapeutics, Inc. is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy

• Abzena Announces a Research and Licence Agreement with Tmunity Therapeutics, a T Cell Engineering Company

  9/19/2018

  Abzena, plc has signed an antibody humanisation agreement with Tmunity Therapeutics

• Tmunity Names Moji James as General Counsel and Executive Vice President

  9/18/2018

  Ms. James formerly served as Senior Vice President, General Counsel and Corporate Secretary of Iroko Pharmaceuticals where she managed various functions including legal, compliance, human resources and corporate communications.

• Tmunity Names Graeme Bell as Chief Financial Officer and Executive Vice President

  9/4/2018

  Mr. Bell formerly served in CFO roles at Intellia Therapeutics, Anacor Pharmaceuticals, and at Merck & Co., Inc. in US and UK operations.

• Tmunity Appoints Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President

  7/10/2018

  Tmunity Therapeutics, Inc. today announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President.

• 

  Bill Gates and Other Tech Billionaires Team Up to Fund Life Science Research

  5/1/2018

  Bill Gates via The Bill and Melinda Gates Foundation and Google co-founder Larry Page, have pledged $12 million to research to develop a universal flu vaccine. However, they aren’t the only tech billionaires to get into funding healthcare and life science research initiatives.

• Tmunity Raises Additional $35 Million in Series A Financing, Bringing Series A Total to $135 Million to Advance Next-Generation T Cell Therapies

  4/19/2018

  Tmunity Therapeutics, Inc. announced an additional $35 million Series A investment from Kleiner Perkins and affiliates.

• 

  New Kid Tmunity Banks $100M From Gilead and Facebook Billionaire Sean Parker

  1/23/2018

  The funds raised will partly go towards funding two clinical trials that have already opened.

• Be The Match BioTherapies Invests in Tmunity Therapeutics to Support Advancement of Next-Generation T cell Immunotherapies

  1/23/2018

  Be The Match BioTherapies®, an organization offering solutions for delivering cellular therapies, today announced that it has invested in Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy.

• 

  Startups Continue Banking Cash

  1/17/2018

  New kid on the block Tmunity just banked a series A funding round worth $100M.

• Tmunity Names Michael Christiano Executive Vice President And Chief Business Officer

  5/9/2017